Fate Therapeutics Inc
Change company Symbol lookup
Select an option...
FATE Fate Therapeutics Inc
FRZA Forza X1 Inc
ILMN Illumina Inc
NR Newpark Resources Inc
CGC Canopy Growth Corp
NAOV Nanovibronix Inc
ETON Eton Pharmaceuticals Inc
LXRX Lexicon Pharmaceuticals Inc
BVS Bioventus Inc
TDS-U Telephone and Data Systems Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.

Closing Price
$4.87
Day's Change
-0.43 (-8.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.37
Day's Low
4.82
Volume
(Heavy Day)
Volume:
2,548,140

10-day average volume:
1,995,987
2,548,140
  • Prev Close
    5.30
  • Today's Open
    5.31
  • Day's Range
    4.82-5.37
  • Avg Vol (10-day)
    2.0M
  • Last (time)
    4:00p ET 06/09/23
  • Last (size)
    159
  • 52-Wk Range
    4.02 - 37.13
    LowHigh
  • (08/08/22 - 01/06/23)
    21.14%
  • 123.5%
  • Market Cap
    479.1M
  • Shares Outstanding
    98.4M
  • -2.42
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.5
  • 110.26
  • (% of float 05/15/23)
    30.05

Latest News

June 08, 2023
9:00 pm ET
BusinessWire
June 05, 2023
11:33 am ET
BusinessWire
May 31, 2023
8:00 am ET
Globe Newswire
May 08, 2023
7:48 pm ET
Newsfile
May 03, 2023
4:01 pm ET
Globe Newswire
May 02, 2023
9:16 am ET
Globe Newswire
9:16 am ET
Globe Newswire
April 24, 2023
8:00 am ET
Globe Newswire
March 30, 2023
12:04 pm ET
Globe Newswire
March 22, 2023
11:35 am ET
BusinessWire
10:30 am ET
Globe Newswire
9:29 am ET
Newsfile
7:48 am ET
Newsfile
5:45 am ET
PR Newswire
March 21, 2023
9:00 pm ET
BusinessWire
6:50 pm ET
Globe Newswire
11:40 am ET
Globe Newswire
10:30 am ET
BusinessWire
9:19 am ET
Newsfile
7:47 am ET
Newsfile
5:45 am ET
PR Newswire
March 20, 2023
6:17 pm ET
Accesswire
1:04 pm ET
Globe Newswire
12:05 pm ET
Globe Newswire
11:04 am ET
Accesswire
10:00 am ET
Globe Newswire
9:14 am ET
Newsfile
9:12 am ET
Accesswire
7:46 am ET
Newsfile
5:45 am ET
PR Newswire
March 19, 2023
11:51 am ET
Newsfile
March 18, 2023
3:30 pm ET
Accesswire
11:00 am ET
PR Newswire
March 17, 2023
9:00 pm ET
Globe Newswire
5:01 pm ET
Accesswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.